UiPath Valuation
Is PATH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PATH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PATH ($14.24) is trading below our estimate of fair value ($16.69)
Significantly Below Fair Value: PATH is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PATH?
Key metric: As PATH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is PATH's PS Ratio? | |
|---|---|
| PS Ratio | 5.7x |
| Sales | US$1.38b |
| Market Cap | US$7.83b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | -38x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PATH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.5x | ||
CVLT Commvault Systems | 8.5x | 10.4% | US$7.6b |
TENB Tenable Holdings | 5.8x | 9.3% | US$5.1b |
QLYS Qualys | 9.5x | 7.2% | US$5.6b |
DLB Dolby Laboratories | 6x | 5.6% | US$7.7b |
PATH UiPath | 5.7x | 9.7% | US$7.8b |
Price-To-Sales vs Peers: PATH is good value based on its Price-To-Sales Ratio (5.7x) compared to the peer average (7.5x).
Price to Sales Ratio vs Industry
How does PATH's PS Ratio compare vs other companies in the US Software Industry?
Price-To-Sales vs Industry: PATH is expensive based on its Price-To-Sales Ratio (5.7x) compared to the US Software industry average (5.3x).
Price to Sales Ratio vs Fair Ratio
What is PATH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.7x |
| Fair PS Ratio | 7x |
Price-To-Sales vs Fair Ratio: PATH is good value based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$14.24 | US$15.53 +9.1% | 9.7% | US$19.00 | US$13.00 | n/a | 17 |
| Nov ’25 | US$12.57 | US$15.53 +23.5% | 9.7% | US$19.00 | US$13.00 | n/a | 17 |
| Oct ’25 | US$12.40 | US$15.76 +27.1% | 9.9% | US$19.00 | US$13.50 | n/a | 17 |
| Sep ’25 | US$12.88 | US$15.18 +17.8% | 11.8% | US$19.00 | US$13.00 | n/a | 17 |
| Aug ’25 | US$11.80 | US$15.47 +31.1% | 12.8% | US$19.00 | US$13.00 | n/a | 17 |
| Jul ’25 | US$12.88 | US$16.21 +25.8% | 19.2% | US$26.00 | US$13.00 | n/a | 17 |
| Jun ’25 | US$12.26 | US$16.00 +30.5% | 20.2% | US$26.00 | US$12.00 | n/a | 17 |
| May ’25 | US$19.24 | US$27.89 +44.9% | 8.3% | US$32.00 | US$24.00 | n/a | 20 |
| Apr ’25 | US$22.19 | US$27.99 +26.1% | 8.3% | US$32.00 | US$24.00 | n/a | 20 |
| Mar ’25 | US$23.63 | US$25.00 +5.8% | 13.3% | US$30.00 | US$17.00 | n/a | 18 |
| Feb ’25 | US$23.11 | US$24.17 +4.6% | 15.2% | US$30.00 | US$17.00 | n/a | 18 |
| Jan ’25 | US$24.84 | US$23.72 -4.5% | 15.1% | US$30.00 | US$17.00 | n/a | 18 |
| Dec ’24 | US$25.04 | US$23.56 -5.9% | 14.7% | US$30.00 | US$17.00 | n/a | 18 |
| Nov ’24 | US$15.52 | US$20.11 +29.6% | 15.4% | US$29.00 | US$16.00 | US$12.57 | 18 |
| Oct ’24 | US$17.11 | US$20.11 +17.5% | 15.4% | US$29.00 | US$16.00 | US$12.40 | 18 |
| Sep ’24 | US$15.89 | US$18.94 +19.2% | 12.7% | US$25.00 | US$16.00 | US$12.88 | 17 |
| Aug ’24 | US$17.79 | US$18.88 +6.1% | 13.0% | US$25.00 | US$16.00 | US$11.80 | 17 |
| Jul ’24 | US$16.57 | US$18.88 +14.0% | 13.0% | US$25.00 | US$16.00 | US$12.88 | 17 |
| Jun ’24 | US$17.93 | US$18.88 +5.3% | 13.0% | US$25.00 | US$16.00 | US$12.26 | 17 |
| May ’24 | US$14.15 | US$19.68 +39.1% | 15.1% | US$27.50 | US$16.00 | US$19.24 | 17 |
| Apr ’24 | US$17.56 | US$19.66 +11.9% | 15.3% | US$27.50 | US$15.00 | US$22.19 | 16 |
| Mar ’24 | US$14.58 | US$17.17 +17.7% | 22.7% | US$27.50 | US$12.00 | US$23.63 | 18 |
| Feb ’24 | US$17.10 | US$17.17 +0.4% | 22.7% | US$27.50 | US$12.00 | US$23.11 | 18 |
| Jan ’24 | US$12.71 | US$17.44 +37.2% | 21.4% | US$27.50 | US$12.00 | US$24.84 | 18 |
| Dec ’23 | US$12.92 | US$17.36 +34.4% | 22.0% | US$27.50 | US$12.00 | US$25.04 | 18 |
| Nov ’23 | US$12.33 | US$17.63 +43.0% | 23.1% | US$30.00 | US$12.00 | US$15.52 | 19 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Dye & Durham
CA$1.2b
Provides cloud-based software and technology solutions for law firms, financial service institutions, sole-practitioner law firms, and government organizations in Canada, Australia, South Africa, Ireland, and the United Kingdom.
DYND.F
CA$12.80
7D
6.1%
1Y
33.2%
Enghouse Systems
CA$1.6b
Develops enterprise software solutions worldwide.
EGHS.F
CA$20.88
7D
-5.3%
1Y
-17.0%
Hackett Group
US$854.3m
Operates as an intellectual property-based executive advisory, strategic consulting, and digital transformation company in the United States, Europe, and internationally.
HCKT
US$30.96
7D
2.1%
1Y
36.6%